Sosei Group (TYO: 4565) and Captor Therapeutics are kicking off a collaboration to discover and develop drugs focused on G protein-coupled receptors (GPCRs).
Sosei, one of leaders in this area, is partnering with the privately-held Polish firm in order to leverage its expertise in targeted protein degradation (TPD).
This approach utilizes the body’s natural process for degrading proteins, diverting the mechanism using small molecules to eliminate diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze